News

Press Center Filter

2018

Thursday 29 November 2018

InspireMD Announces Positive Long-Term Safety and Efficacy Data from Ongoing CGuard™ EPS Registries at the Recent 45th Annual Symposium on Vascular and Endovascular Issues, Techniques, Horizons (VEITHsymposium)

Tel Aviv, Israel— November 29, 2018 – InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of…

Wednesday 28 November 2018

InspireMD Announces Regulatory and Reimbursement Approval of CGuard™ Embolic Prevention System in Australia Commercial Launch to Occur Immediately

Tel Aviv, Israel— November 28, 2018 – InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of…

Tuesday 13 November 2018

InspireMD Announces Upcoming Presentations at the 45th Annual Symposium on Vascular and Endovascular Issues, Techniques, Horizons (VEITHsymposium)

Tel Aviv, Israel— November 13, 2018 – InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of…

Tuesday 06 November 2018

InspireMD Announces Third Quarter 2018 Financial Results and Provides Corporate Update

Presented Three-Year Data Highlighting Long-Term Safety and Efficacy of CGuard™ Embolic Prevention System   On-Track to Submit U.S. IDE in Mid-2019 Company to Host Investor Conference Call at 8:00am ET…

Tuesday 30 October 2018

InspireMD to Report Third Quarter 2018 Financial Results and Provide Business Update on Tuesday, November 6

Conference Call Scheduled for 8am Eastern Time Tel Aviv, Israel— October 30, 2018 – InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention…

Thursday 27 September 2018

InspireMD Announces Presentation of Preliminary Cumulative Three-Year CGuard™ EPS Safety and Efficacy Data at the Transcatheter Cardiovascular Therapeutics 2018 Conference

Preliminary Three-Year Data Continue to Show Unprecedented Safety, Efficacy and Durability of Stroke Prevention in Treating Carotid Artery Stenosis Tel Aviv, Israel— September 27, 2018 – InspireMD, Inc. (NYSE American:…

Monday 24 September 2018

InspireMD Announces Regulatory Approval of CGuard™ Embolic Prevention System in Mexico

Commercial Launch to Occur Immediately   Tel Aviv, Israel— September 24, 2018 – InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of…

Monday 17 September 2018

InspireMD Announces Issuance of Two New U.S. Patents Covering Proprietary MicroNet™ Stent Jacket and Related Drug Eluting Technology

Patents further strengthen intellectual property surrounding Company’s lead commercial product, CGuard™ EPS  InspireMD remains on track to submit an Investigational Device Exception (IDE) with FDA in mid-2019 Tel Aviv, Israel—…

Tuesday 04 September 2018

InspireMD to Present at the H.C. Wainwright 20th Annual Global Investment Conference in New York City

Tel Aviv, Israel— September 4, 2018 – InspireMD, Inc. (NYSE American:NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of carotid…

Monday 06 August 2018

InspireMD Reports 94% Increase in CGuard™ EPS RevenuesInspireMD Reports 94% Increase in CGuard™ EPS Revenuesfor the Second Quarter of 2018

Tel Aviv, Israel— August 6, 2018 – InspireMD, Inc. (NYSE American:NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of carotid…

Tuesday 31 July 2018

InspireMD Schedules Second Quarter 2018 Earnings Conference Call

Tel Aviv – July 31, 2018 – InspireMD, Inc. (NYSE: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of carotid…

Monday 23 July 2018

InspireMD Announces Opening of First Two CGuard™ EPS Centers of Excellence

Tel Aviv, Israel— July 23, 2018 – InspireMD, Inc. (NYSE AMER: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of…

Friday 29 June 2018

InspireMD, Inc. Announces Pricing of $10 Million Underwritten Public Offering

Tel Aviv, Israel— June 29, 2018 – InspireMD, Inc. (NYSE American: NSPR), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today announced the pricing…

Wednesday 20 June 2018

InspireMD’s CGuard™ EPS Featured at the SBHCI Congress in Brazil

Tel Aviv, Israel— June 20, 2018 – InspireMD, Inc. (NYSE AMER:NSPR), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today announced that CGuard™ EPS…

Monday 18 June 2018

InspireMD’s CGuard™ EPS Prominently Featured at the 10th International Congress of the Polish Society for Vascular Surgery

Study results presented from 46 patients treated over two years with zero complications President of the Polish Society for Vascular Surgery presented clinical cases illustrating the advantages of CGuard™ EPS…

Monday 11 June 2018

InspireMD’s CGuard™ MicroNet™ EPS Featured in a Live Case Transmission to the 2nd DGA Interventional Congress

Tel Aviv, Israel— June 11, 2018 – InspireMD, Inc. (NYSE AMER:NSPR), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today announced that its CGuard™…

Wednesday 30 May 2018

InspireMD Reports on Expanded 2 Year Follow-up Results from the PARADIGM Clinical Study Using CGuard™ EPS

Results Presented at EuroPCR 2018 Confirm Sustained Safety and Cerebral Embolic Prevention out to 24 months Tel Aviv, Israel— May 30, 2018 –  InspireMD, Inc. (NYSE AMER:NSPR), a leader in embolic prevention…

Wednesday 16 May 2018

InspireMD Receives Regulatory Approval for both CGuard™ EPS and MGuard Prime™ in Ecuador

Tel Aviv, Israel— May 16, 2018 –  InspireMD, Inc. (NYSE AMER:NSPR), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today announced that it has received…

Tuesday 08 May 2018

InspireMD Reports 132% Increase in CGuard™ EPS Sales for the First Quarter of 2018

Tel Aviv, Israel— May 7, 2018 – InspireMD, Inc. (NYSE American:NSPR), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today announced results for the…

Tuesday 01 May 2018

InspireMD Schedules First Quarter 2018 Earnings Conference Call

Tel Aviv – May 1, 2018 – InspireMD, Inc. (NYSE: NSPR), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today announced that it will…

Monday 30 April 2018

InspireMD Announces Regulatory Approval and Reimbursement to Commercialize both CGuard™ EPS and MGuard Prime™ Products in Vietnam

Tel Aviv, Israel— April 30, 2018 – InspireMD, Inc. (NYSE AMER:NSPR), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today announced it has received regulatory approval,…

Thursday 19 April 2018

InspireMD’s CGuard™ Embolic Prevention System to be Featured at ICCA Stroke 2018 in Warsaw, PolandInspireMD’s CGuard™ Embolic Prevention System to be Featured at ICCA Stroke 2018 in Warsaw, Poland

 Tel Aviv, Israel— April 19, 2018 – InspireMD, Inc. (NYSE AMER:NSPR), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today announced that its CGuard™ Embolic Prevention…

Tuesday 03 April 2018

InspireMD Anticipates Fifth Consecutive Quarter of Sequential Double Digit Growth; Projects 132% Increase in CGuard™ EPS Sales for the First Quarter of 2018; Total Quarterly Company Sales to Exceed $1 Million

Tel Aviv, Israel— April 3, 2018 – InspireMD, Inc. (NYSE AMER:NSPR), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today announced preliminary unaudited sales results for…

Wednesday 28 March 2018

InspireMD, Inc. Announces Pricing of $5.0 Million Public Offering of Common Stock

Tel Aviv, Israel— March 28, 2018 – InspireMD, Inc. (NYSE American: NSPR),  a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today announced the pricing of an…

Wednesday 28 March 2018

InspireMD, Inc. Announces Proposed Public Offering of Common Stock

Tel Aviv, Israel— March 27, 2018 – InspireMD, Inc. (NYSE American: NSPR),  a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today announced that it intends to…

Tuesday 27 March 2018

InspireMD Receives Regulatory Approval for both CGuard™ EPS and MGuard Prime™ in Peru

Tel Aviv, Israel— March 27, 2018 – InspireMD, Inc. (NYSE AMER:NSPR), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today announced that it has received regulatory…

Monday 05 March 2018

InspireMD Announces First Patient Treated with CGuardTM EPS in India

Patient with severe stenosis, calcification and thrombosis successfully treated with CGuardTM EPS   Tel Aviv, Israel— March 5, 2018 – InspireMD, Inc. (NYSE AMER:NSPR), a leader in embolic prevention systems (EPS) /…

Thursday 01 March 2018

InspireMD Announces Expansion of its Distribution Network

Tel Aviv, Israel— March 1, 2018 – InspireMD, Inc. (NYSE AMER:NSPR), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today announced it has signed an exclusive…

Tuesday 27 February 2018

InspireMD, Inc. Announces Pricing of Public Offering of Common Stock

Tel Aviv, Israel— February 27, 2018 – InspireMD, Inc. (NYSE American: NSPR),  a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today announced the pricing of an…

Tuesday 27 February 2018

InspireMD, Inc. Announces Proposed Public Offering of Common Stock

Tel Aviv, Israel— February 26, 2018 – InspireMD, Inc. (NYSE American: NSPR),  a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today announced that it intends to…

Thursday 22 February 2018

InspireMD Announces Exclusive Distribution, Sales and Marketing Agreement for CGuard™ EPS in South Korea

Solvit Medical to fund all regulatory, registration and reimbursement submissions Tel Aviv, Israel— February 22, 2018 – InspireMD, Inc. (NYSE AMER:NSPR), a leader in embolic prevention systems (EPS) / thrombus management technologies…

Tuesday 20 February 2018

InspireMD Announces Commercial Launch and First Sales of CGuard™ EPS in India

Tel Aviv, Israel— February 20, 2018 – InspireMD, Inc. (NYSE American:NSPR), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today announced the commercial launch and first…

Wednesday 14 February 2018

InspireMD Announces Fourth Quarter and Year-End 2017 Results; CGuard™ EPS Fourth Quarter Sales Increase 211% Versus Same Period Last year

Tel Aviv, Israel— February 14, 2018 – InspireMD, Inc. (NYSE American:NSPR), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today announced results for the…

Wednesday 07 February 2018

InspireMD Announces 1-for-35 Reverse Stock Split

Tel Aviv, Israel— February 7, 2018 – InspireMD, Inc. (NYSE American: NSPR, NSPR.WS, NSPR.WSB), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today announced…

Wednesday 31 January 2018

InspireMD’s CGuard™ Embolic Prevention System Featured in a Second Live Case Transmission at LINC 2018 by Leading Interventional Cardiologists

Tel Aviv, Israel— January 31, 2018 – InspireMD, Inc. (NYSE AMER:NSPR), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today announced that its CGuard™…

Tuesday 30 January 2018

InspireMD’s CGuard™ Embolic Prevention System Featured in Successful Live Case Transmissions at LINC 2018 by Leading Vascular Surgeons

Tel Aviv, Israel— January 30, 2018 – InspireMD, Inc. (NYSE AMER:NSPR), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today announced that its CGuard™…

Friday 26 January 2018

InspireMD’s CGuard™ Embolic Prevention System to be Prominently Featured in Two Live Case Transmissions at LINC 2018

Tel Aviv, Israel— January 26, 2018 – InspireMD, Inc.  (NYSE AMER:NSPR), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today announced that its CGuard™ Embolic…

Friday 19 January 2018

InspireMD Announces Publication of an Independent Imaging Study Highlighting the Advantages of CGuard™ EPS Compared to Another Next Generation Carotid Stent

Tel Aviv, Israel— January 19, 2018 – InspireMD, Inc. (NYSE AMER:NSPR), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today announced the publication of an independent…

Wednesday 10 January 2018

InspireMD Projects 211% Increase in CGuard™ EPS Sales for the Fourth Quarter of 2017

Conference call to be held at 10AM Eastern today to discuss recent developments, preliminary sales results and proposals for upcoming shareholder meeting   Tel Aviv, Israel— January 10, 2018 – InspireMD,…

Thursday 04 January 2018

InspireMD Schedules Conference Call to Discuss Recent Developments, Preliminary Sales Results and Proposals for Upcoming Shareholder Meeting

Tel Aviv—January 3, 2018 – InspireMD, Inc. (NYSE AMER:NSPR), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today announced that it will host a conference call…

Wednesday 03 January 2018

InspireMD Announces Regulatory Approval of CGuard™ EPS in India; Signs Agreement with Leading Indian Medical Device Distributor

Tel Aviv, Israel— January 3, 2018 – InspireMD, Inc. (NYSE AMER:NSPR), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today announced that it has received regulatory…

2017

Monday 18 December 2017

InspireMD’s CGuard™ Embolic Prevention System Once Again Featured in a Successful Live Clinical Case at Leading Industry Conference

Professor Pierfrancesco Veroux treated a patient with carotid artery disease using CGuard™ EPS Tel Aviv, Israel— December 18, 2017 – InspireMD, Inc.  (NYSE AMER:NSPR), a leader in embolic prevention systems (EPS)…

Thursday 07 December 2017

InspireMD’s CGuard™ EPS Demonstrates Improved Outcomes over Carotid Endarterectomy in 50 Patient Comparative Study; Preliminary Results Featured at the 7th Munich Vascular Conference 2017

Tel Aviv, Israel— December 7, 2017 – InspireMD, Inc.  (NYSE AMER:NSPR), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today announced that Professor Ralf Kolvenbach,…

Wednesday 06 December 2017

InspireMD Announces Preliminary 2 Year Follow-up Results from the PARADIGM Clinical Study Using CGuard™ EPS

No procedure or device related adverse events at 24 months Results presented at the 2017 VEITHsymposium in New York and ICI Meeting 2017 in Tel Aviv Tel Aviv, Israel— December…

Monday 04 December 2017

InspireMD Announces Expansion of its Distribution Network for CGuard™ EPS in Australia, New Zealand and Vietnam

Tel Aviv, Israel— December 4, 2017 – InspireMD, Inc. (NYSE AMER:NSPR), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today announced it has signed Diverse Devices…

Wednesday 29 November 2017

InspireMD Announces Planned Recapitalization

Tel Aviv, Israel— November 29, 2017 – InspireMD, Inc. (NYSE MKT:NSPR), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today announced that it entered into a…

Wednesday 08 November 2017

InspireMD Announces Third Quarter 2017 Results; CGuard™ Revenue Increases 90% Versus Same Period Last year

Tel Aviv, Israel—November 7, 2017 – InspireMD, Inc. (NYSE AMER:NSPR), a leader in Embolic Prevention Systems (EPS) / thrombus management technologies and neurovascular devices, today announced preliminary results for the third quarter…

Wednesday 01 November 2017

InspireMD Schedules Third Quarter 2017 Earnings Conference Call

Tel Aviv—November 1, 2017 – InspireMD, Inc. (NYSE AMER:NSPR), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today announced that it will host a conference call…

Wednesday 25 October 2017

InspireMD’s CGuard™ Carotid Embolic Prevention System Featured in Live Case at Cracow Vascular Summit 2017 in Poland

Prof. Waclaw Kuczmik performed successful case treating a patient with carotid artery disease with CGuard™ EPS in Katowice Clinical Hospital Tel Aviv, Israel – October 25, 2017 – InspireMD, Inc. (NYSE AMER:NSPR)…

Tuesday 24 October 2017

New York Stock Exchange Accepts InspireMD’s Plan to Regain Compliance

Tel Aviv, Israel – October 24, 2017 – InspireMD, Inc. (NYSE AMER:NSPR) (NYSE AMER:NSPR.WS) (“InspireMD” or the “Company”), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices,…

Friday 13 October 2017

InspireMD Announces Distribution Agreement for MGuard Prime™ in Chile

Tel Aviv, Israel—October 12, 2017 – InspireMD, Inc. (NYSE AMER:NSPR), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today announced it has signed an agreement with…

Tuesday 10 October 2017

InspireMD Announces the Start of Patient Enrollment in an Investigator Initiated Trial of CGuard™ EPS in Russia

CGuard™ Embolic Prevention System (EPS) to be Randomized Against Abbott’s RX ACCULINK® Carotid Stent System Tel Aviv, Israel—October 9, 2017 – InspireMD, Inc. (NYSE AMER:NSPR), a leader in Embolic Prevention Systems (EPS)…

Wednesday 04 October 2017

InspireMD Postpones Special Meeting of Stockholders to October 27, 2017

Tel Aviv, Israel—October 4, 2017 – InspireMD, Inc. (NYSE AMER:NSPR) (NYSE AMER:NSPR.WS) (“InspireMD” or the “Company”), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today announced…

Thursday 21 September 2017

InspireMD Announces Distribution Agreement for CGuardTM EPS in Portugal

Tel Aviv, Israel—September 21, 2017 – InspireMD, Inc. (NYSE AMER:NSPR) (NYSE AMER:NSPR.WS) (“InspireMD” or the “Company”), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today announced…

Thursday 07 September 2017

InspireMD to Present at the 19th Annual Rodman & Renshaw Global Investment Conference in New York City

 Tel Aviv, Israel—September 6, 2017 – InspireMD, Inc. (NYSE AMER:NSPR) (NYSE AMER:NSPR.WS) (“InspireMD” or the “Company”), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today announced…

Friday 25 August 2017

InspireMD Announces Distribution Agreement for CGuardTM EPS in Switzerland

Tel Aviv, Israel—August 25, 2017 – InspireMD, Inc. (NYSE AMER:NSPR) (NYSE AMER:NSPR.WS) (“InspireMD” or the “Company”), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today announced…

Tuesday 22 August 2017

InspireMD Shares CGuardTM EPS Video Testimonials from European Key Opinion Leaders

Tel Aviv—August 22, 2017 – InspireMD, Inc. (NYSE AMER:NSPR) (NYSE AMER:NSPR.WS) (“InspireMD” or the “Company”), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today announced it…

Tuesday 22 August 2017

InspireMD Announces Notification of NYSE AMERICAN Listing Deficiency and Expectation to Regain Compliance

Tel Aviv– August 22, 2017 — InspireMD, Inc. (NYSE AMER: NSPR) (“InspireMD” or the “Company”), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today…

Wednesday 09 August 2017

InspireMD Reports Double Digit Sequential and Year-Over-Year Revenue Growth for the Second Quarter of 2017

Completes Transition to Local Distribution Network Across Europe  CGuard Sales in European Countries Transitioned Back from Former Distributor Increase 122% Versus Q1 2017 Tel Aviv—August 8, 2017 – InspireMD, Inc. (NYSE MKT:NSPR)…

Monday 07 August 2017

InspireMD Announces Publication of an Independent Clinical Review Authored by Leading U.S. and European Physicians Supporting Safety Advantages of Mesh-Covered Carotid Stents

 Comprehensive Review of Clinical Trial Data Supports the Safety and Efficacy of Carotid Artery Stenting (CAS) Versus Carotid Endarterectomy (CEA)  Mesh Covered Carotid Devices Transforming the CAS Field  Highlights Key…

Thursday 03 August 2017

InspireMD’s CGuard™ Carotid Embolic Prevention System Featured at the SOLACI CACI Congress of Cardiology 2017 in Buenos Aires

CGuardTM EPS procedure recorded and broadcast to the entire congress Tel Aviv, Israel – August 3, 2017 – InspireMD, Inc. (NYSE MKT:NSPR) (NYSE MKT:NSPR.WS) (“InspireMD” or the “Company”), a leader in embolic…

Wednesday 02 August 2017

InspireMD Schedules Second Quarter 2017 Earnings Conference Call

Tel Aviv—August 2, 2017 – InspireMD, Inc. (NYSE MKT:NSPR) (NYSE MKT:NSPR.WS) (“InspireMD” or the “Company”), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today…

Tuesday 13 June 2017

InspireMD Announces Completion of Transition from Exclusive European Distributor to InspireMD Managed Local Distribution Network

Agreements Completed with Leading Distributors in Austria and Belgium Tel Aviv, Israel—June 13, 2017 – InspireMD, Inc. (NYSE MKT:NSPR) (NYSE MKT:NSPR.WS) (“InspireMD” or the “Company”), a leader in embolic prevention systems (EPS)…

Thursday 08 June 2017

InspireMD Announces Distribution Agreement for CGuard™ EPS in Taiwan

Tel Aviv, Israel—June 8, 2017 – InspireMD, Inc. (NYSE MKT:NSPR) (NYSE MKT:NSPR.WS) (“InspireMD” or the “Company”), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today announced…

Wednesday 07 June 2017

InspireMD Announces the Publication of an Investigator Initiated Clinical Registry Reaffirming MGuardTM Prime as a Highly Effective Tool to Prevent Heart Damage in Coronary Artery Blockages with High Thrombotic Content

Study Entitled “Long term Outcomes of MGuard™ Stent Deployment in Saphenous Vein Grafts and Native Coronary Arteries: A Single Center Experience”  Tel Aviv, Israel—June 7, 2017 – InspireMD, Inc. (NYSE MKT:NSPR) (NYSE…

Monday 05 June 2017

InspireMD Announces Distribution Agreement for CGuardTM EPS in Poland

Tel Aviv, Israel—June 5, 2017 – InspireMD, Inc. (NYSE MKT:NSPR) (NYSE MKT:NSPR.WS) (“InspireMD” or the “Company”), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today announced…

Friday 02 June 2017

InspireMD Announces Appointment of Paul Stuka as Chairman of the Board

Tel Aviv, Israel—June 2, 2017 – InspireMD, Inc. (NYSE MKT:NSPR) (NYSE MKT:NSPR.WS) (“InspireMD” or the “Company”), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today announced…

Thursday 01 June 2017

InspireMD to Present at the 6th Annual SeeThruEquity Microcap Investor Conference

NEW YORK, NY / ACCESSWIRE / May 31, 2017 / InspireMD, Inc. (NYSE MKT:NSPR) (NYSE MKT:NSPR.WS) (“InspireMD” or the “Company”), a leader in embolic prevention systems (EPS) / thrombus management…

Tuesday 30 May 2017

InspireMD Announces First Two Patients in Hong Kong Successfully Treated with CGuard™ EPS

Tel Aviv, Israel—May 30, 2017 – InspireMD, Inc. (NYSE MKT:NSPR) (NYSE MKT:NSPR.WS) (“InspireMD” or the “Company”), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today announced…

Thursday 18 May 2017

InspireMD’s CGuard™ Carotid Embolic Prevention System Featured in Live Case Transmission at EuroPCR 2017

Prof. Alberto Cremonesi’s team performed successful case   treating a patient with carotid artery disease with CGuard™ EPS   Tel Aviv, Israel – May 18, 2017 – InspireMD, Inc. (NYSE MKT:NSPR) (NYSE…

Wednesday 17 May 2017

InspireMD Announces Publication of the IRON-GUARD Registry in EuroIntervention

Zero incidence of major adverse cardiovascular events including no major strokes   BOSTON, MA—May 17, 2017 – InspireMD, Inc. (NYSE MKT:NSPR) (NYSE MKT:NSPR.WS) (“InspireMD” or the “Company”), a leader in embolic prevention…

Monday 15 May 2017

InspireMD Announces Distribution Agreements for CGuard™ EPS and MGuard Prime™ EPS in Peru and Ecuador

BOSTON, MA—May 15, 2017 – InspireMD, Inc. (NYSE MKT:NSPR) (NYSE MKT:NSPR.WS) (“InspireMD” or the “Company”), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today announced it…

Tuesday 09 May 2017

InspireMD Provides Business Update for the First Quarter of 2017

New Commercial Roll-Out of CGuard™ EPS on Schedule  84% Sequential Increase in Sales of CGuard™   Tel Aviv—May 9, 2017 – InspireMD, Inc. (NYSE MKT:NSPR) (NYSE MKT:NSPR.WS) (“InspireMD” or the “Company”), a…

Sunday 07 May 2017

InspireMD Schedules First Quarter 2017 Earnings Conference Call

Tel Aviv—May X, 2017 – InspireMD, Inc. (NYSE MKT:NSPR) (NYSE MKT:NSPR.WS) (“InspireMD” or the “Company”), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today announced that…

Monday 01 May 2017

InspireMD Announces Distribution Agreement for CGuardTM EPS in Germany

Tel Aviv—May 1, 2017 – InspireMD, Inc. (NYSE MKT:NSPR) (NYSE MKT:NSPR.WS) (“InspireMD” or the “Company”), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today announced it…

Thursday 06 April 2017

InspireMD Announces Distribution Agreement for CGuardTM EPS in the Netherlands

Tel Aviv—April 6, 2017 – InspireMD, Inc. (NYSE MKT:NSPR) (NYSE MKT:NSPR.WS) (“InspireMD” or the “Company”), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today announced it…

Wednesday 05 April 2017

InspireMD Announces Listing of Series B Warrants on the NYSE MKT

Tel Aviv—April 5, 2017 – InspireMD, Inc. (NYSE MKT:NSPR) (NYSE MKT:NSPR.WS) (“InspireMD” or the “Company”), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today announced the…

Tuesday 04 April 2017

InspireMD Announces Distribution Agreement for CGuardTM in Turkey

Tel Aviv—April 4, 2017 – InspireMD, Inc. (NYSE MKT:NSPR) (NYSE MKT:NSPR.WS) (“InspireMD” or the “Company”), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today announced it…

Thursday 30 March 2017

InspireMD Announces Commercial Launch of CGuard™ EPS in the Russian Federation at the ICCA Stroke Event In Moscow

BOSTON, MA—March 30, 2017 – InspireMD, Inc. (NYSE MKT:NSPR) (NYSE MKT:NSPR.WS) (“InspireMD” or the “Company”), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today announced the…

Thursday 23 March 2017

InspireMD’s CGuard™ Carotid Embolic Prevention System to be Featured at ICCA Stroke 2017 in Moscow, Russia

BOSTON, MA—March 23, 2017 – InspireMD, Inc. (NYSE MKT:NSPR) (NYSE MKT:NSPR.WS) (“InspireMD” or the “Company”), a leader in embolic prevention systems (EPS), neurovascular devices and thrombus management technologies, today announced that its…

Wednesday 22 March 2017

InspireMD Repays Term Note Ahead of Schedule

Tel Aviv—March 22, 2017 – InspireMD, Inc. (NYSE MKT:NSPR) (NYSE MKT:NSPR.WS) (“InspireMD” or the “Company”), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today announced that…

Tuesday 21 March 2017

InspireMD Announces Distribution Agreement for CGuard™ EPS in Hong Kong

BOSTON, MA—March 21, 2017 – InspireMD, Inc. (NYSE MKT:NSPR) (NYSE MKT:NSPR.WS) (“InspireMD” or the “Company”), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today announced it…

Monday 20 March 2017

InspireMD Announces CGuardTM Distribution Agreement for the Russian Federation

Tel Aviv—March 20, 2017 – InspireMD, Inc. (NYSE MKT:NSPR) (NYSE MKT:NSPR.WS) (“InspireMD” or the “Company”), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today announced it…

Wednesday 15 March 2017

InspireMD Reports Continued Progress in the Transition of European Sales and Distribution

Announces Agreements with Leading Distributors in the Baltic States   BOSTON, MA—March 15, 2017 – InspireMD, Inc. (NYSE MKT:NSPR) (NYSE MKT:NSPR.WS) (“InspireMD” or the “Company”), a leader in embolic prevention systems (EPS)…

Tuesday 14 March 2017

InspireMD Announces Closing of Public Offering of Approximately $6.8 Million

BOSTON, MA – March 14, 2017 – InspireMD, Inc. (NYSE MKT: NSPR) (“InspireMD” or the “Company”), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices,…

Thursday 09 March 2017

InspireMD Announces Pricing of Public Offering of up to $7.5 Million

BOSTON, MA – March 9, 2017 – InspireMD, Inc. (NYSE MKT: NSPR) (“InspireMD” or the “Company”), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices,…

Thursday 16 February 2017

InspireMD Provides Year End Business Update and Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2016

Transition from Exclusive Distribution Partner to Local Distributors and Internal Sales Strategy Validated by Strong Revenue Growth in Select Markets   BOSTON, MA—February 16, 2017 – InspireMD, Inc. (NYSE MKT:NSPR) (NYSE MKT:NSPR.WS)…

Tuesday 24 January 2017

InspireMD’s CGuard™ Carotid Embolic Prevention System to be Featured at LINC 2017

PD Dr. Andrej Schmidt to perform live case transmission of carotid stent surgery utilizing CGuard™ BOSTON, MA– January 24, 2016 – InspireMD, Inc. (NYSE MKT:NSPR) (NYSE MKT:NSPR.WS) (“InspireMD” or the “Company”), a…

2016

Monday 05 December 2016

InspireMD Announces Change in Presentation Time at LD Micro Main Event Conference to Tuesday, December 6 at 4:30PM PT

BOSTON, Mass. – December 5, 2016 – InspireMD, Inc. (NYSE MKT: NSPR, NSPR.WS) (“InspireMD” or the “Company”), a leader in embolic prevention systems (EPS), neurovascular devices and thrombus management technologies,…

Monday 28 November 2016

InspireMD to Present at LD Micro Main Event on December 6

BOSTON, Mass. – November 28, 2016 – InspireMD, Inc. (NYSE MKT: NSPR, NSPR.WS) (“InspireMD” or the “Company”), a leader in embolic prevention systems (EPS), neurovascular devices and thrombus management technologies,…

Monday 14 November 2016

InspireMD Reports Financial Results for the Third Quarter Ended September 30, 2016

– Company to Host Conference Call Today at 4:30pm ET – BOSTON, MA – November 14, 2016 – InspireMD, Inc. (NYSE MKT: NSPR, NSPR.WS) (“InspireMD” or the “Company”), a leader…

Monday 14 November 2016

InspireMD Announces CGuardTM Embolic Prevention System Commercialization Approval in Russia

BOSTON, MA – November 14, 2016 – InspireMD, Inc. (NYSE MKT: NSPR) (“InspireMD” or the “Company”), a leader in embolic prevention systems (EPS), neurovascular devices and thrombus management technologies, today announced…

Monday 07 November 2016

InspireMD to Report Third Quarter Financial Results on Monday, November 14, 2016

BOSTON, MA – November 7, 2016 – InspireMD, Inc. (NYSE MKT: NSPR.WS), a leader in embolic protection systems, announced today that it will release its financial results for the third…

Tuesday 01 November 2016

InspireMD CGuard™ Embolic Prevention System 12-Month Clinical Trial Data Further Validate Potential of CGuard™ to Improve Management of Carotid Artery Disease and Prevent Stroke

BOSTON, MA – November 1, 2016 – InspireMD, Inc. (NYSE MKT: NSPR, NSPR.WS) (“InspireMD” or the “Company”), a leader in embolic prevention systems (EPS), neurovascular devices and thrombus management technologies,…

Thursday 27 October 2016

Long-term Clinical Data on InspireMD’s CGuard™ Embolic Prevention System to be Presented at Transcatheter Cardiovascular Therapeutics (TCT) Scientific Symposium

Presentations Highlight Potential for CGuard™ to Improve Management of Carotid Artery Disease and Prevent Stroke BOSTON, MA – October 27, 2016 – InspireMD, Inc. (NYSE MKT: NSPR, NSPR.WS) (“InspireMD” or…

Wednesday 26 October 2016

InspireMD Announces Appointment of Medical Device Industry Veteran Agustin Gago as Chief Commercial Officer

BOSTON, MA – October 26, 2016 – InspireMD, Inc. (NYSE MKT: NSPR, NSPR.WS) (“InspireMD” or the “Company”), a leader in embolic prevention systems (EPS), neurovascular devices and thrombus management technologies,…

Monday 17 October 2016

InspireMD Announces Independent Study Published in the Journal of Endovascular Therapy that Continues to Support the Clinical Benefit and Utility of the CGuard™ Embolic Prevention System

100% procedural success rate in a 30 patient study using the new CGuardTM Embolic Prevention System with no procedural related complications and zero strokes at 6-month follow up Companion Editorial…

Thursday 13 October 2016

InspireMD to Present at the Dawson James Securities 2nd Annual Growth Stock Conference on October 20

BOSTON, Mass. – October 13, 2016 – InspireMD, Inc. (NYSE MKT: NSPR, NSPR.WS) (“InspireMD” or the “Company”), a leader in embolic prevention systems (EPS), neurovascular devices and thrombus management technologies,…

Thursday 06 October 2016

InspireMD Announces Adjustments to Shares Receivable Upon Warrant Exercise and Exercise Price Per Share

BOSTON, MA – October 6, 2016 – InspireMD, Inc. (NYSE MKT: NSPR, NSPR.WS) (“InspireMD” or the “Company”), a leader in embolic prevention systems (EPS), neurovascular devices and thrombus management technologies,…

Wednesday 28 September 2016

InspireMD Announces 1-for-25 Reverse Stock Split

BOSTON, MA – September 28, 2016 – InspireMD, Inc. (NYSE MKT: NSPR, NSPR.WS) (“InspireMD” or the “Company”), a leader in embolic prevention systems (EPS), neurovascular devices and thrombus management technologies,…

Wednesday 07 September 2016

InspireMD Appoints Thomas Kester to Board of Directors

BOSTON, MA – September 7, 2016 – InspireMD, Inc. (NYSE MKT: NSPR, NSPR.WS) (“InspireMD” or the “Company”), a leader in embolic prevention systems (EPS), neurovascular devices and thrombus management technologies,…

Tuesday 09 August 2016

InspireMD Reports Financial Results for the Second Quarter Ended June 30, 2016

 Company to Host Conference Call Today at 4:30pm ET BOSTON, MA – August 9, 2016 – InspireMD, Inc. (NYSE MKT: NSPR, NSPR.WS) (“InspireMD” or the “Company”), a leader in embolic…

Tuesday 02 August 2016

InspireMD to Report Second Quarter Financial Results on Tuesday, August 9, 2016

BOSTON, MA – August 2, 2016 – InspireMD, Inc. (NYSE MKT: NSPR, NSPR.WS), a leader in embolic protection systems, announced today that it will release its financial results for the…

Monday 01 August 2016

InspireMD Announces Listing of Warrants on the NYSE MKT

BOSTON, MA – August 1, 2016 — InspireMD, Inc. (NYSE MKT: NSPR, NSPR.WS) (“InspireMD” or the “Company”), a leader in embolic protection systems (EPS), neurovascular devices and thrombus management technologies,…

Thursday 21 July 2016

InspireMD Regains Compliance with NYSE MKT Listing Standards

BOSTON, MA – July 21, 2016 — InspireMD, Inc. (NYSE MKT: NSPR) (“InspireMD” or the “Company”), a leader in embolic protection systems (EPS), neurovascular devices and thrombus management technologies, today…

Thursday 07 July 2016

InspireMD Announces Closing of Public Offering of Approximately $14.6 Million

BOSTON, MA – July 7, 2016 – InspireMD, Inc. (NYSE MKT: NSPR) (“InspireMD” or the “Company”), a leader in embolic prevention systems (EPS), neurovascular devices and thrombus management technologies, today…

Friday 01 July 2016

InspireMD Announces Pricing of Public Offering of Approximately $14.6 Million

BOSTON, MA – June 30, 2016 – InspireMD, Inc. (NYSE MKT: NSPR) (“InspireMD” or the “Company”), a leader in embolic prevention systems (EPS), neurovascular devices and thrombus management technologies, today…

Tuesday 14 June 2016

InspireMD Announces Amendment to Loan & Security Agreement with Hercules Capital

Principal Payments Deferred, Assisting Cash Management Programs   BOSTON, MA – June 14, 2016 – InspireMD, Inc. (NYSE MKT: NSPR) (“InspireMD” or the “Company”), a leader in embolic prevention systems…

Tuesday 07 June 2016

InspireMD Names Dr. James Barry as President and CEO

Medical Device Veteran Brings Broad Industry Experience in Pioneering Technologies BOSTON, MA – June 7, 2016 – InspireMD, Inc. (NYSE MKT: NSPR) (“InspireMD” or the “Company”), a leader in embolic…

Tuesday 17 May 2016

InspireMD’s CGuardTM Highlighted at the Late-Breaking Clinical Trial Session at the EuroPCR 2016 Conference

BOSTON, MA – May 17, 2016 – InspireMD, Inc. (NYSE MKT: NSPR) (“InspireMD” or the “Company”), a leader in embolic prevention systems (EPS), neurovascular devices and thrombus management technologies, today…

Tuesday 10 May 2016

InspireMD Reports Financial Results for the First Quarter Ended March 31, 2016

BOSTON, MA – May 10, 2016 – InspireMD, Inc. (NYSE MKT: NSPR) (“InspireMD” or the “Company”), a leader in embolic prevention systems (EPS), neurovascular devices and thrombus management technologies, today…

Thursday 05 May 2016

InspireMD Announces Late-Breaking Trial Presentation on CGuardTM Embolic Prevention System at EuroPCR 2016 Conference

BOSTON, MA – May 5, 2016 – InspireMD, Inc. (NYSE MKT: NSPR) (“InspireMD” or the “Company”), a leader in embolic prevention systems (EPS), neurovascular devices and thrombus management technologies, today…

Thursday 31 March 2016

InspireMD Receives Audit Opinion with Going Concern Explanation

BOSTON, MA – March 31, 2016 – InspireMD, Inc. (NYSE MKT: NSPR) (“InspireMD” or the “Company”), a leader in embolic prevention systems (EPS), neurovascular devices and thrombus management technologies, today…

Monday 28 March 2016

InspireMD Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2015

BOSTON, MA – March 28, 2016 – InspireMD, Inc. (NYSE MKT: NSPR) (“InspireMD” or the “Company”), a leader in embolic prevention systems (EPS), neurovascular devices and thrombus management technologies, today…

Monday 21 March 2016

InspireMD Announces Closing of Public Offering

BOSTON, MA – March 21, 2016 – InspireMD, Inc. (“InspireMD” or the “Company”) (NYSE MKT: NSPR), a leader in embolic protection systems (“EPS”), today announced the closing of an underwritten public offering of…

Monday 21 March 2016

InspireMD Announces Closing of Private Placement to Certain Officers and Directors

BOSTON, MA – March 21, 2016 – InspireMD, Inc. (“InspireMD” or the “Company”) (NYSE MKT: NSPR), a leader in embolic protection systems (“EPS”), today announced the closing of its private placement of 1,033,051…

Wednesday 16 March 2016

InspireMD Announces Pricing of Public Offering

BOSTON, MA – March 16, 2016 – InspireMD, Inc. (“InspireMD” or the “Company”) (NYSE MKT: NSPR), a leader in embolic protection systems (“EPS”), today announced the pricing of an underwritten…

Wednesday 16 March 2016

InspireMD Announces Private Placement to Certain Officers and Directors

BOSTON, MA – March 16, 2016 – InspireMD, Inc. (“InspireMD” or the “Company”) (NYSE MKT: NSPR), a leader in embolic protection systems (“EPS”), today announced a private placement (the “Private…

Tuesday 15 March 2016

InspireMD Announces Proposed Public Offering of Common Stock and Warrants

BOSTON, MA – March 15, 2016 – InspireMD, Inc. (“InspireMD” or the “Company”) (NYSE MKT: NSPR), a leader in embolic protection systems (“EPS”), today announced that it intends to offer and sell, subject…

Friday 22 January 2016

InspireMD Aligns Operations and Leadership Team, Appoints Isaac Blech as Vice Chairman of the Board

Enhances Commercial and Development Execution Reduces Operating Cost Structure Strengthens Board of Directors   BOSTON, MA – January 22, 2016 – InspireMD, Inc. (NYSE MKT: NSPR) (“InspireMD” or the “Company”),…

2015

Wednesday 02 December 2015

InspireMD Receives EU Regulatory Approval for Additional Supplier of CGuardTM Delivery Catheters

BOSTON, MA – December 2, 2015 – InspireMD, Inc. (NYSE MKT: NSPR) (“InspireMD” or the “Company”), a leader in embolic prevention systems (EPS), neurovascular devices and thrombus management technologies, announced…

Friday 20 November 2015

InspireMD Announces Positive Twelve Month Follow-Up CARENET Trial Data at VEITH Symposium 2015

 BOSTON, MA – November 20, 2015 – InspireMD, Inc. (NYSE MKT: NSPR) (“InspireMD” or the “Company”), a leader in embolic prevention systems (EPS), neurovascular devices and thrombus management technologies, announced…

Tuesday 10 November 2015

InspireMD Reports Financial Results for the Third Quarter Ended September 30, 2015

BOSTON, MA – November 10, 2015 – InspireMD, Inc. (NYSE MKT: NSPR) (“InspireMD” or the “Company”), a leader in embolic prevention systems (EPS), neurovascular devices and thrombus management technologies, today…

Monday 02 November 2015

InspireMD to Report Financial Results for the Third Quarter Ended September 30, 2015 on Tuesday, November 10th

BOSTON, MA – November 2, 2015 – InspireMD, Inc. (NYSE MKT: NSPR) (“InspireMD” or the “Company”), a leader in embolic prevention systems (EPS), neurovascular devices and thrombus management technologies, announced…

Monday 19 October 2015

InspireMD Announces CGuardTM Approval in Argentina

CGuardTM Clinical Data Presented at TCT 2015 Carotid Scientific Sessions   BOSTON, MA – October 19, 2015 – InspireMD, Inc. (NYSE MKT: NSPR) (“InspireMD” or the “Company”), a leader in…

Thursday 08 October 2015

InspireMD to Present at Dawson James Securities Growth Stock Conference

BOSTON, MA – September 8, 2015 – InspireMD, Inc. (NYSE MKT: NSPR) (“InspireMD” or the “Company”), a leader in embolic prevention systems (EPS), neurovascular devices and thrombus management technologies, announced…

Monday 05 October 2015

InspireMD Announces CGuardTM Approval in Colombia

BOSTON, MA – October 5, 2015 – InspireMD, Inc. (NYSE MKT: NSPR) (“InspireMD” or the “Company”), a leader in embolic prevention systems (EPS), neurovascular devices and thrombus management technologies, announced…

Thursday 01 October 2015

InspireMD Announces One-for-Ten Reverse Stock Split

BOSTON, MA – October 1, 2015 – InspireMD, Inc. (NYSE MKT: NSPR) (“InspireMD” or the “Company”), a leader in embolic prevention systems (EPS), neurovascular devices and thrombus management technologies, announced…

Monday 28 September 2015

InspireMD Announces Full Market Launch of CGuardTM Distributed by Penumbra at CIRSE Annual Congress

BOSTON, MA – September 28, 2015 – InspireMD, Inc. (NYSE MKT: NSPR) (“InspireMD” or the “Company”), a leader in embolic prevention systems (EPS), neurovascular devices and thrombus management technologies, announced…

Thursday 17 September 2015

InspireMD Announces the Issuance of Two United States Patents

Continued Focus on Intellectual Property Results in Continued Portfolio Expansion BOSTON, MA – September 17, 2015 – InspireMD, Inc. (NYSE MKT: NSPR) (“InspireMD” or the “Company”) a leader in embolic…

Wednesday 09 September 2015

InspireMD Announces Allowance of US Patent Claims

Continues to Strengthen and Broaden Intellectual Property Portfolio   BOSTON, MA – September 9, 2015 – InspireMD, Inc. (NYSE MKT: NSPR) (“InspireMD” or the “Company”) a leader in embolic prevention…

Tuesday 01 September 2015

InspireMD to Present at the Rodman & Renshaw 17th Annual Global Investment Conference

BOSTON, MA – September 1, 2015 – InspireMD, Inc. (NYSE MKT: NSPR) a leader in stent embolic prevention systems (“EPS”) and thrombus management technologies, today announced that its Chief Executive…

Wednesday 05 August 2015

InspireMD Reports Financial Results for the Second Quarter Ended June 30, 2015

BOSTON, MA – August 5, 2015 – InspireMD, Inc. (NYSE MKT: NSPR) (“InspireMD” or the “Company”), a leader in stent embolic prevention systems (“EPS”), today announced its financial and operating…

Wednesday 05 August 2015

InspireMD Announces Distribution Partnership of its CGuardTM Embolic Prevention System with Penumbra, Inc.

Accelerates InspireMD’s Access into Key Geographic & Specialty Markets Enables CGuardTM to be Commercialized as Part of a Total Systems Solution BOSTON, MA – August 5, 2015 – InspireMD, Inc….

Tuesday 14 July 2015

InspireMD to Report Financial Results for the Second Quarter Ended June 30, 2015 on Wednesday, August 5th

BOSTON, MA – July 14, 2015 – InspireMD, Inc. (NYSE MKT: NSPR) (“InspireMD” or the “Company”), a leader in embolic protection systems, announced today that it will release its full…

Tuesday 07 July 2015

InspireMD Receives Frost & Sullivan 2015 European Coronary Stent New Product Innovation Award

Recognized for Successful Introduction of New and Innovative Products, with Emphasis on Quality and Customer Value BOSTON, MA – July 7, 2015 — InspireMD, Inc. (NYSE MKT: NSPR) (“InspireMD” or the…

Friday 22 May 2015

InspireMD’s CGuard™ Highlighted at Clinical Presentation at EuroPCR 2015 Conference

PARADIGM Evaluation Reports CGuard™ Favorable Outcomes in All-Comer Carotid Disease Population BOSTON, MA – May 12, 2015 — InspireMD, Inc. (NYSE MKT: NSPR) (“InspireMD” or the “Company”), a leader in…

Tuesday 12 May 2015

InspireMD Announces Clinical Presentations on CGuard™ and MGuard™ Systems with MicroNet™ Technology at EuroPCR 2015 Conference

Clinical Presentations Highlight Carotid and Coronary Applications of InspireMD’s Proprietary MicroNet™ Technology BOSTON, MA – May 12, 2015 — InspireMD, Inc. (NYSE MKT: NSPR) (“InspireMD” or the “Company”), a leader…

Monday 11 May 2015

InspireMD Reports Financial Results for the First Quarter Ended March 31, 2015

BOSTON, MA – May 11, 2015 — InspireMD, Inc. (NYSE MKT: NSPR) (“InspireMD” or the “Company”), a leader in embolic protection systems (“EPS”), today announced its financial and operating results…

Monday 27 April 2015

InspireMD Announces MGuard™ Prime Approval in Brazil

BOSTON, MA – April 27, 2015 — InspireMD, Inc. (NYSE MKT: NSPR) (“InspireMD” or the “Company”), today announced it received approval to commercialize MGuard™ Prime™ with MicroNet™ technology in Brazil….

Wednesday 15 April 2015

InspireMD Announces Completion of Sales Restructuring Program

BOSTON, MA – April 15, 2015 — InspireMD, Inc. (NYSE MKT: NSPR) (“InspireMD” or the “Company”), a leader in embolic protection systems (“EPS”), today announced the completion of its sales…

Monday 16 March 2015

InspireMD Plan of Compliance Accepted by NYSE MKT

BOSTON, MA – March 16, 2015 — InspireMD, Inc. (NYSE MKT: NSPR) (“InspireMD” or the “Company”), a leader in embolic protection systems (“EPS”), announced today that the New York Stock…

Thursday 12 March 2015

InspireMD Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2014

BOSTON, MA – March 12, 2015 – InspireMD, Inc. (NYSE MKT: NSPR) (“InspireMD” or the “Company”), a leader in stent embolic protection systems (“EPS”), today announced its financial and operating…

Monday 09 March 2015

InspireMD Announces Closing of Public Offering for Approximately $13.7 Million

BOSTON, MA – March 9, 2015 — InspireMD, Inc. (NYSE MKT: NSPR) (“InspireMD” or the “Company”), a leader in embolic protection systems (“EPS”), today announced the closing of its offering…

Friday 06 March 2015

InspireMD to Report Financial Results for the Fourth Quarter and Year Ended December 31, 2014 on Thursday, March 12th

BOSTON, MA – March 6, 2015 — InspireMD, Inc. (NYSE MKT: NSPR) (“InspireMD” or the “Company”), a leader in embolic protection systems (“EPS”), announced today that it will release its…

Wednesday 04 March 2015

InspireMD Announces Proposed Public Offering of Common Stock and Warrants

BOSTON, MA – March 4, 2015 — InspireMD, Inc. (NYSE MKT: NSPR) (“InspireMD” or the “Company”), a leader in embolic protection systems (“EPS”), today announced that it intends to offer…

Wednesday 04 March 2015

InspireMD Announces Public Offering for Approximately $13.5 Million

BOSTON, MA – March 3, 2015 — InspireMD, Inc. (NYSE MKT: NSPR) (“InspireMD” or the “Company”), a leader in embolic protection systems (“EPS”), today announced that it has entered into…

Friday 27 February 2015

InspireMD to Present at the Cowen and Company 35th Annual Healthcare Conference

Presentation to be Webcast on March 3, 2015 at 10:40 a.m. ET BOSTON, MA – February 26, 2015 — InspireMD, Inc. (NYSE MKT: NSPR) (“InspireMD” or the “Company”), a leader…

Tuesday 27 January 2015

InspireMD Receives CE Mark Approval for Its New CGuard RX and Announces Positive Six Month Follow-Up CARENET Trial Data at LINC 2015

The New CGuardTM RX Rapid Exchange System Receives CE Mark Approval Six-Month Ultrasound Analysis Confirms Widely Patent Internal and External Carotid Arteries When Compared to Conventional Carotid Stents   BOSTON,…

Wednesday 21 January 2015

InspireMD Announces Notification of NYSE MKT Listing Deficiency

BOSTON, MA – January 21, 2015 — InspireMD, Inc. (NYSE MKT: NSPR) (“InspireMD” or the “Company”), a leader in embolic protection systems (“EPS”), today announced the receipt of a notice…

Tuesday 13 January 2015

InspireMD to Announce Positive Six Month Results from the CGuardTM CARENET Trial at LINC 2015

CGuardTM All Comer Data Continues to Show Excellent Clinical Benefits of the MicroNetTM Covered Technology Six-Month Ultrasound Analysis is Indicative of Patent Carotid Arteries Without Restenosis Concern When Compared to…

Monday 05 January 2015

InspireMD Pre-Announces a Fourth Quarter 2014 Revenue Increase of 200% Over the Third Quarter of 2014 and Provides Update on Corporate and Commercial Strategies

Near-term Focus On Carotid and DES Products, Streamlined Operations   BOSTON, MA – January 5, 2015 — InspireMD, Inc. (NYSE MKT: NSPR) (“InspireMD” or the “Company”), a leader in embolic…

2014

Monday 15 December 2014

InspireMD Announces Important Clinical Data from MASTER and CARENET Trials

MASTER I and MASTER II Pooled Data Show Statistically Significant Mortality Benefit  CARENET 30 Day DW-MRI Data Demonstrates Significant Reduction in New Ischemic Ipsilateral Lesions BOSTON, MA – December 15, 2014…

Wednesday 12 November 2014

InspireMD Reports Financial Results for the Third Quarter ended September 30, 2014

Master II 30 day data to be presented December 15th at the ICI Meeting 2014, Tel-Aviv  Announced first pre-clinical implant with partner DES platform BOSTON, MA – November 12, 2014…

Friday 07 November 2014

InspireMD Completes $8.1 Million Registered Direct Offering

BOSTON, MA – November 7, 2014 – InspireMD, Inc. (“InspireMD” or the “Company”) (NYSE MKT: NSPR), a leader in stent Embolic Protection Systems (EPS), today announced the closing of its registered direct offering…

Wednesday 05 November 2014

InspireMD to Report Financial Results for the Third Quarter Ended September 30, 2014 on Wednesday, November 12th

BOSTON, MA – November 5, 2014 – InspireMD, Inc. (NYSE MKT: NSPR) (“InspireMD” or the “Company”), a leader in stent embolic protection systems, announced today that it will release its…

Tuesday 04 November 2014

InspireMD Announces Registered Direct Offering for Approximately $8 Million

BOSTON, MA – November 4, 2014 – InspireMD, Inc. (“InspireMD” or the “Company”) (NYSE MKT: NSPR), a leader in stent Embolic Protection Systems (EPS), today announced that it has entered into a definitive…

Wednesday 29 October 2014

InspireMD Investigational Device Exemption (IDE) Amendment Approved by the FDA

Validation of manufacturing process changes for the MGuard Prime EPS BOSTON, MA – October 29, 2014 – InspireMD, Inc. (“InspireMD” or the “Company”) (NYSE MKT: NSPR), a leader in Embolic Protection Systems (EPS),…

Tuesday 14 October 2014

InspireMD Resumes MGuard Prime Sales and Prioritizes DES and Carotid – New Product Programs

MGuard Prime commercial re-launch complete in direct markets   Drug Eluting Stent (DES) program advances in development with partners — MASTER II trial to suspend enrollment to support DES and…

Wednesday 01 October 2014

InspireMD Announces Initial Commercial Sales of the CGuard™ EPS

BOSTON, MA – October 1, 2014 – InspireMD, Inc. (“InspireMD” or the “Company”) (NYSE MKT: NSPR), a leader in embolic protection systems (EPS), today announced that it has recorded the first commercial sales…

Thursday 18 September 2014

InspireMD to Host Conference Call and Webinar and to Discuss Recently Released Results of CGuard™ CARENET Trial on September 24th

CARENET Trial data presented at the Transcatheter Cardiovascular Therapeutics (TCT) conference, September 16, 2014,showed 0% MACE at 30 Days   BOSTON, MA – September 18, 2014 — InspireMD, Inc.(NYSE MKT:…

Tuesday 16 September 2014

InspireMD Announces Positive Results from CGuard™ CARENET Trial with 0% MACE reported at 30 Days

Achieved Primary 30 Day Endpoint   Patients in CARENET Trial had significantly lower incidence of new ischemic lesions    compared to historical control groups of non-mesh covered carotid stents   BOSTON,…

Wednesday 03 September 2014

InspireMD to Present at the Aegis Healthcare and Technology Conference

BOSTON, MA – September 03, 2014 — InspireMD, Inc.(NYSE MKT: NSPR) (“InspireMD” or the “Company”), a leader in embolic protection systems (“EPS”), today announced that its Chief Financial Officer, Craig…

Monday 11 August 2014

InspireMD to Announce Results of CGuard™ CARENET Trial at the TCT Innovation Session on Late Breaking Early Human Clinical Studies

Results will be announced on Tuesday, September 16in Washington, D.C. BOSTON, MA – August 11, 2014 — InspireMD, Inc.(NYSE MKT: NSPR) (“InspireMD” or the “Company”), a leader in embolic protection…

Wednesday 23 July 2014

InspireMD Reports Financial Results for the Second Quarter Ended June 30, 2014

BOSTON, MA – July 23, 2014 – InspireMD, Inc.(NYSE MKT: NSPR) (“InspireMD” or the “Company”), a leader in embolic protection systems (“EPS”), today announced its financial and operating results for…

Thursday 17 July 2014

InspireMD to Report Financial Results for the Second Quarter Ended June 30, 2014 on Wednesday, July 23rd

BOSTON, MA – July 17, 2014 – InspireMD, Inc. (NYSE MKT: NSPR) (“InspireMD” or the “Company”), a leader in embolic protection systems, announced today that it will release its financial…

Tuesday 15 July 2014

InspireMD Appoints Dr. James Barry as Chief Operating Officer

Strengthens Leadership Team with Addition of Experienced Medical Device Executive   BOSTON, MA – July 15, 2014 – InspireMD, Inc.(NYSE MKT: NSPR) (“InspireMD” or the “Company”), a leader in embolic…

Tuesday 08 July 2014

InspireMD Announces Successful Completion of CGuard™ CARENET (CARotid Embolic protection study using microNET) Trial

100% procedural success rate achieved in first multi-specialty clinical experience BOSTON, MA – July 8, 2014 — InspireMD, Inc.(NYSE MKT: NSPR) (“InspireMD” or the “Company”), a leader in embolic protection…

Tuesday 01 July 2014

InspireMD Selected for Inclusion in the Russell Microcap Index

BOSTON, MA – July 1, 2014 — InspireMD Inc.(NYSE MKT: NSPR) (“InspireMD” or the “Company”), a leader in embolic protection systems, today announced that it has been selected to join…

Monday 23 June 2014

InspireMD Receives European Regulatory Approval to Resume Manufacturing and Distribution of MGuardTM Prime EPS

BOSTON, MA – June 23, 2014 – InspireMD, Inc. (“InspireMD” or the “Company”) (NYSE MKT: NSPR), a leader in embolic protection systems (EPS), today announced that it received European regulatory approval to resume…

Wednesday 18 June 2014

InspireMD to Present at the 9th Annual JMP Securities Healthcare Conference

BOSTON, MA – June 18, 2014 – InspireMD, Inc. (NYSE MKT: NSPR) (“InspireMD” or the “Company”), today announced that its CEO, Alan Milinazzo, will be presenting at the 9th Annual…

Wednesday 07 May 2014

InspireMD Reports Financial Results for the First Quarter Ended March 31, 2014

BOSTON, MA – May 7, 2014 – InspireMD, Inc. (NYSE MKT: NSPR) (“InspireMD” or the “Company”), a leader in embolic protection systems (“EPS”), today announced financial and operating results for…

Wednesday 07 May 2014

InspireMD Announces Positive Results from iMOS Prime Registry for the MGuard Prime EPS

Study of 97 patients resulted in zero mortalities in STEMI patients as of 30-day follow up Results to be presented at EuroPCR meeting in Paris on Thursday, May 22nd at…

Wednesday 30 April 2014

InspireMD Announces Voluntary Field Action for MGuardTM Prime EPS

BOSTON, MA – April 30, 2014 – InspireMD, Inc. (“InspireMD” or the “Company”) (NYSE MKT: NSPR), a leader in embolic protection systems (EPS), today announced that it has initiated a Voluntary Field Action…

Wednesday 30 April 2014

InspireMD to Report Financial Results for Quarter Ended March 31, 2014 on Wednesday, May 7th

BOSTON, MA – April 30, 2014 – InspireMD, Inc. (NYSE MKT: NSPR) (“InspireMD” or the “Company”), a leader in embolic protection stents, announced today that it will release its financial results…

Wednesday 19 March 2014

InspireMD Announces First Patient Enrolled Into New CGuard™ CARENET (CARotid Embolic protection study using microNET) Clinical Trial

Proven Embolic Protection System Expands to Treat Carotid Artery Disease   BOSTON, MA – March 19, 2014 – InspireMD, Inc. (“InspireMD” or the “Company”) (NYSE MKT: NSPR), a leader in embolic protection systems,…

Thursday 06 March 2014

InspireMD to Present at the 26th Annual ROTH Conference

BOSTON, MA – March 6, 2014 – InspireMD, Inc. (NYSE MKT: NSPR) (“InspireMD” or the “Company”), today announced that its CEO, Alan Milinazzo, will be presenting at the 26th Annual…

Thursday 27 February 2014

InspireMD to Present at the Cowen & Company 34th Annual Health Care Conference

BOSTON, MA – February 27, 2014 – InspireMD, Inc. (NYSE MKT: NSPR) (“InspireMD” or the “Company”), today announced that its CEO, Alan Milinazzo, will be presenting at the Cowen &…

Wednesday 26 February 2014

InspireMD Reports Financial Results for the Quarter and Six Month Period Ended December 31, 2013

BOSTON, MA – February 26, 2014 – InspireMD Inc. (NYSE MKT: NSPR) (“InspireMD” or the “Company”), a leader in embolic protection systems, today announced financial and operating results for the…

Tuesday 18 February 2014

InspireMD to Report Financial Results for Six Month Period Ended December 31, 2013 on Wednesday, February 26, 2014

BOSTON, MA – February 18, 2014 – InspireMD, Inc. (NYSE MKT: NSPR) (“InspireMD” or the “Company”), a leader in embolic protection stents, announced today that it will release its financial results…

Wednesday 05 February 2014

InspireMD Reports Successful Implantation of the New CGuardTM Carotid Embolic System with MicroNetTM Technology

Acclaimed Embolic Protection System Expands to Treat Carotid Artery Disease   BOSTON, MA – February 5, 2014 – InspireMD, Inc. (“InspireMD” or the “Company”) (NYSE MKT: NSPR), a leader in embolic protection systems,…

2013

Tuesday 03 December 2013

InspireMD to Present at the 24th Annual Oppenheimer & Co. Healthcare Conference in New York City on December 11th

BOSTON, MA – December 3, 2013 – InspireMD, Inc. (NYSE MKT: NSPR) (“InspireMD” or the “Company”), today announced that its CEO, Alan Milinazzo will be presenting at the 24th Annual…

Monday 02 December 2013

InspireMD Appoints Rick Olson as Vice President of Global Sales Operations

Company Strengthens Leadership Team with Addition of Experienced Global Sales Executive   BOSTON, MA – December 2, 2013 – InspireMD Inc. (NYSE MKT: NSPR) (“InspireMD” or the “Company”), a leader…

Tuesday 19 November 2013

InspireMD Announces Upcoming Investor Event in Israel

Company to Host Investor Event on December 2, 2013 at 5:00 p.m. IST   BOSTON, MA – November 19, 2013 – InspireMD, Inc. (“InspireMD” or the “Company”) (NYSE MKT: NSPR),…

Monday 11 November 2013

InspireMD Reports Financial Results for Quarter Ended September 30, 2013

BOSTON, MA – November 11, 2013 – InspireMD Inc. (NYSE MKT: NSPR) (“InspireMD” or the “Company”), a leader in embolic protection stents, today announced financial results for the quarter ended…

Tuesday 29 October 2013

InspireMD’s MGuard Stent Shows Lower Mortality Rate in STEMI Patients at Twelve Months Compared to Control Group

Company to Host Conference Call Tomorrow at 5:30 a.m. PT / 8:30 a.m. ET BOSTON, MA – October 29, 2013 – InspireMD, Inc. (“InspireMD” or the “Company”) (NYSE MKT: NSPR), a…

Monday 28 October 2013

InspireMD Schedules Conference Call to Discuss MASTER Trial 12-month Follow-Up Data

BOSTON, MA – October 28, 2013 – InspireMD, Inc. (NYSE MKT: NSPR) (“InspireMD” or the “Company”), a leader in embolic protection stents, announced today that it will host a conference call…

Thursday 24 October 2013

InspireMD Files At-the-Market Offering and Shelf Registration Statement

BOSTON, MA – October 24, 2013 – InspireMD Inc. (NYSE MKT: NSPR) (“InspireMD” or the “Company”), a leader in embolic protection stents, announced today that it has filed a $75…

Thursday 24 October 2013

InspireMD Secures Financing to Accelerate Advancements in Product Development and Adopts a One Year Stockholder Rights Plan

Funding for expansion of clinical trial and product development strategies   BOSTON, MA – October 24, 2013 – InspireMD Inc. (NYSE MKT: NSPR) (“InspireMD” or the “Company”), a leader in…

Wednesday 23 October 2013

InspireMD to Ring Opening Bell at New York Stock Exchange on Thursday, October 24th

BOSTON, MA – October 23, 2013 – InspireMD, Inc. (NYSE MKT: NSPR) (“InspireMD” or the “Company”), a leader in embolic protection stents, announced today that it will ring the Opening Bell…